Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)
Acta Dermato-Venereologica · 2024
DOI: 10.2340/actadv.v104.40556 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Acta Dermato-Venereologica, 2024. Verfasst von April W Armstrong und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Los Angeles, CA, USA. aprilarmstrong@post.harvard.edu. Hauptthemen laut MEDLINE: Psoriasis, Severity of Illness Index, Biological Products. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Despite the abundance of data concerning biologic treatments for patients with psoriasis, clinicians are often challenged with discerning the optimal treatment for each patient. To inform this selection, this study explored whether a patient’s baseline characteristics or disease profile could predict the likelihood of achieving complete skin clearance with biologic treatment. Machine-learning and other statistical methods were applied to the substantial data collected from patients with moderate-to-severe psoriasis in the ongoing, international, prospective, observational Psoriasis Study of Health Outcomes (PSoHO). The 3 measures of complete skin clearance were a psoriasis area and severity index (PASI)100 response at (a) week 12, (b) month 12, and (c) week 12 and maintain ed at month 6 and month 12 (PASI100 durability). From these real-world data, the absence of nail psoriasis emerged as the most consistent feature that may be used by clinicians to predict high-level treatment responses with biologic treatment. Other significant predictors of skin clearance with biologic treatments were the absence of hypertension and a lower body surface area affected by psoriasis. Overall, this study evidences the substantial challenge of identifying reliable clinical markers of treatment response for patients with psoriasis and highlights the importance of regular screening for psoriatic nail involvement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of California, Los Angeles, CA, USA. aprilarmstrong@post.harvard.edu.
- Department of Dermatology, Medical University of Vienna, Vienna, Austria.
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
- Dermatology Unit, Department of Medicine, University of Padova, Padua, Italy.
- Division of Dermatology, Department of Medicine, Tygerberg Academic Hospital and Stellenbosch University, Cape Town, South Africa.
- Eli Lilly and Company, Indianapolis, USA.
Förderung
- Eli Lilly and Company
Zitieren
APA
Armstrong, A. W., Riedl, E., Brunner, P. M., Piaserico, S., Visser, W. I., Haustrup, N., Konicek, B. W., Kadziola, Z., Nunez, M., Brnabic, A., & Schuster, C. (2024). Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO). Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v104.40556
Vancouver
Armstrong AW, Riedl E, Brunner PM, Piaserico S, Visser WI, Haustrup N, et al. Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO). Acta Dermato-Venereologica. 2024. doi:10.2340/actadv.v104.40556
BibTeX
@article{Armstrong2024,
author = {Armstrong, April W and Riedl, Elisabeth and Brunner, Patrick M and Piaserico, Stefano and Visser, Willie I and Haustrup, Natalie and Konicek, Bruce W and Kadziola, Zbigniew and Nunez, Mercedes and Brnabic, Alan and Schuster, Christopher},
title = {Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)},
journal = {Acta Dermato-Venereologica},
year = {2024},
doi = {10.2340/actadv.v104.40556}
}
EUVIMED